Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Some equations used to calculate estimated glomerular filtration rate (eGFR) may alter chemotherapy dosing in cancer patients ...

Researchers at Cold Spring Harbor Laboratory have found that blocking the FGFR2 and EGFR genes can stop early-stage ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Patients with EGFR-positive non-small cell lung cancer (NSCLC) do not respond as well to immunotherapy as patients without an EGFR mutation. Nevertheless, recent studies indicate that subsequent ...

Circulating tumor cell (CTC) analysis is a promising minimally invasive biomarker for monitoring treatment response and stratifying prognosis in EGFR-mutant non-small cell lung cancer (NSCLC).

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

With the latest overall survival win in hand, J&J believes it holds the key to ending Tagrisso’s long reign in first-line EGFR lung cancer. Previously, the FDA greenlighted Rybrevant and ...